Ampio Pharmaceuticals, Inc. (AMPE)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 9.26 Million USD | -55.94% |
| 2022 | 20.38 Million USD | -0.92% |
| 2021 | 20.57 Million USD | 29.92% |
| 2020 | 15.83 Million USD | -14.76% |
| 2019 | 18.57 Million USD | 66.1% |
| 2018 | 11.18 Million USD | -28.15% |
| 2017 | 15.56 Million USD | -8.88% |
| 2016 | 17.08 Million USD | -49.9% |
| 2015 | 34.09 Million USD | -12.91% |
| 2014 | 39.14 Million USD | 62.62% |
| 2013 | 24.07 Million USD | 102.8% |
| 2012 | 11.87 Million USD | 6.44% |
| 2011 | 11.15 Million USD | 66.35% |
| 2010 | 6.7 Million USD | 30552.91% |
| 2009 | 21.87 Thousand USD | -25.18% |
| 2008 | 29.23 Thousand USD | 0.79% |
| 2007 | 29 Thousand USD | 2788.65% |
| 2006 | 1004.00 USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 FY | 9.26 Million USD | -54.53% |
| 2023 Q2 | 1.56 Million USD | -64.08% |
| 2023 Q1 | 4.34 Million USD | 60.79% |
| 2023 Q3 | 1.4 Million USD | -10.26% |
| 2023 Q4 | 2.21 Million USD | 58.21% |
| 2022 Q3 | 5.72 Million USD | 14.72% |
| 2022 Q1 | 6.97 Million USD | -24.47% |
| 2022 FY | 20.38 Million USD | -0.92% |
| 2022 Q4 | 2.7 Million USD | -52.8% |
| 2022 Q2 | 4.98 Million USD | -28.44% |
| 2021 Q4 | 9.22 Million USD | 139.63% |
| 2021 Q3 | 3.85 Million USD | 4.85% |
| 2021 Q1 | 3.81 Million USD | -2.35% |
| 2021 Q2 | 3.67 Million USD | -3.82% |
| 2021 FY | 20.57 Million USD | 29.92% |
| 2020 Q2 | 2.6 Million USD | -56.82% |
| 2020 FY | 15.83 Million USD | -14.76% |
| 2020 Q1 | 6.02 Million USD | -15.74% |
| 2020 Q3 | 3.3 Million USD | 27.0% |
| 2020 Q4 | 3.91 Million USD | 18.44% |
| 2019 Q3 | 5.17 Million USD | 44.43% |
| 2019 FY | 18.57 Million USD | 66.1% |
| 2019 Q4 | 7.14 Million USD | 38.15% |
| 2019 Q2 | 3.58 Million USD | 33.83% |
| 2019 Q1 | 2.67 Million USD | 5.48% |
| 2018 Q3 | 1.94 Million USD | -38.01% |
| 2018 Q4 | 2.53 Million USD | 30.77% |
| 2018 FY | 11.18 Million USD | -28.15% |
| 2018 Q1 | 3.56 Million USD | -25.77% |
| 2018 Q2 | 3.12 Million USD | -12.24% |
| 2017 Q2 | 4.69 Million USD | 56.18% |
| 2017 FY | 15.56 Million USD | -8.88% |
| 2017 Q4 | 4.8 Million USD | 56.72% |
| 2017 Q3 | 3.06 Million USD | -34.64% |
| 2017 Q1 | 3 Million USD | 1.86% |
| 2016 FY | 17.08 Million USD | -49.9% |
| 2016 Q4 | 2.94 Million USD | -11.83% |
| 2016 Q2 | 4.36 Million USD | -31.99% |
| 2016 Q1 | 6.42 Million USD | -39.03% |
| 2016 Q3 | 3.34 Million USD | -23.44% |
| 2015 Q4 | 10.53 Million USD | 29.69% |
| 2015 Q2 | 7.81 Million USD | 2.59% |
| 2015 Q1 | 7.62 Million USD | -25.13% |
| 2015 Q3 | 8.12 Million USD | 3.89% |
| 2015 FY | 34.09 Million USD | -12.91% |
| 2014 Q2 | 8.96 Million USD | -14.55% |
| 2014 Q4 | 10.17 Million USD | 6.95% |
| 2014 Q3 | 9.51 Million USD | 6.21% |
| 2014 FY | 39.14 Million USD | 62.62% |
| 2014 Q1 | 10.48 Million USD | 38.91% |
| 2013 FY | 24.07 Million USD | 102.8% |
| 2013 Q2 | 6.46 Million USD | 57.84% |
| 2013 Q3 | 5.95 Million USD | -7.94% |
| 2013 Q4 | 7.54 Million USD | 26.77% |
| 2013 Q1 | 4.09 Million USD | 8.72% |
| 2012 Q4 | 3.76 Million USD | 34.0% |
| 2012 FY | 11.87 Million USD | 6.44% |
| 2012 Q3 | 2.81 Million USD | 23.46% |
| 2012 Q2 | 2.27 Million USD | -24.27% |
| 2012 Q1 | 3 Million USD | -34.06% |
| 2011 Q4 | 4.56 Million USD | 64.36% |
| 2011 Q1 | 2.23 Million USD | 35.68% |
| 2011 FY | 11.15 Million USD | 66.35% |
| 2011 Q3 | 2.77 Million USD | 76.08% |
| 2011 Q2 | 1.57 Million USD | -29.53% |
| 2010 Q1 | 1.47 Million USD | 32427.09% |
| 2010 Q2 | 1.14 Million USD | -22.68% |
| 2010 Q3 | 2.43 Million USD | 112.75% |
| 2010 Q4 | 1.64 Million USD | -32.22% |
| 2010 FY | 6.7 Million USD | 30552.91% |
| 2009 FY | 21.87 Thousand USD | -25.18% |
| 2009 Q1 | 9704.00 USD | 131.82% |
| 2009 Q4 | 4547.00 USD | 15.11% |
| 2009 Q3 | 3950.00 USD | 7.6% |
| 2009 Q2 | 3671.00 USD | -62.17% |
| 2008 Q2 | 2697.00 USD | -81.7% |
| 2008 Q3 | 6376.00 USD | 136.41% |
| 2008 Q4 | 4186.00 USD | -34.35% |
| 2008 FY | 29.23 Thousand USD | 0.79% |
| 2008 Q1 | 14.74 Thousand USD | 134.53% |
| 2007 Q4 | 6285.00 USD | -14.2% |
| 2007 Q1 | 300.00 USD | 19.52% |
| 2007 Q2 | 15.09 Thousand USD | 4930.67% |
| 2007 FY | 29 Thousand USD | 2788.65% |
| 2007 Q3 | 7325.00 USD | -51.46% |
| 2006 FY | 1004.00 USD | 0.0% |
| 2006 Q4 | 251.00 USD | 0.0% |
| 2006 Q3 | 251.00 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 32.07 Million USD | 71.106% |
| Armata Pharmaceuticals, Inc. | 11.64 Million USD | 20.44% |
| Actinium Pharmaceuticals, Inc. | 52 Million USD | 82.177% |
| Azitra, Inc. | 8.3 Million USD | -11.63% |
| Can-Fite BioPharma Ltd. | 8.93 Million USD | -3.692% |
| Chromocell Therapeutics Corporation | 6.86 Million USD | -35.057% |
| Calidi Biotherapeutics, Inc. | 28.99 Million USD | 68.033% |
| CEL-SCI Corporation | 31.47 Million USD | 70.555% |
| iBio, Inc. | 16.85 Million USD | 45.026% |
| Lineage Cell Therapeutics, Inc. | 33 Million USD | 71.921% |
| MAIA Biotechnology, Inc. | 20.18 Million USD | 54.079% |
| Matinas BioPharma Holdings, Inc. | 24.86 Million USD | 62.722% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | 33.475% |
| NovaBay Pharmaceuticals, Inc. | 12.89 Million USD | 28.144% |
| NanoViricides, Inc. | 8.51 Million USD | -8.829% |
| Oragenics, Inc. | 5.45 Million USD | -69.994% |
| BiomX Inc. | 26.81 Million USD | 65.436% |
| BiomX Inc. | 26.81 Million USD | 65.436% |
| Protalix BioTherapeutics, Inc. | 32.05 Million USD | 71.084% |
| Palatin Technologies, Inc. | 34.67 Million USD | 73.268% |
| Scorpius Holdings, Inc. | 39.81 Million USD | 76.723% |